Ones To Watch News
Refine Search
Biotechnology
San Diego, USA-based Janux Therapeutics has seen its share price triple after positive early data were announced for JANX007 and JANX008. 28 February 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics was trading more than 50% higher by late Wednesday. 28 February 2024
Biotechnology
US neurodegenerative diseases focussed biotech Denali Therapeutics saw its shares rocket more than 38% to $23.35, on news of a $500 million private placement. 28 February 2024
Pharmaceutical
Shares of biotech FibroGen leapt 14.6% to $2.12 by close of trading Tuesday, after it announced a deal with UK pharma major AstraZeneca for roxadustat would be terminated. 28 February 2024
Biotechnology
France-based ophthalmology biotech PulseSight Therapeutics launches today with seed finance from Pureos Bioventures and ND Capital. 28 February 2024
Pharmaceutical
French ophthalmology company Nicox has announced it will replace its chief executive, Andreas Segerros, with current chief business officer Gavin Spencer. 28 February 2024
Pharmaceutical
USA-based Pelage Pharmaceuticals, a clinical-stage regenerative medicine company developing treatments for hair loss, has closed a $16.75 million Series A financing. 27 February 2024
Biotechnology
Chinese oncology specialist BeiGene has ended its collaboration with privately-held Shoreline Biosciences. 27 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved the marketing application for Exblifep (cefepime/enmetazobactam), submitted by Franco-German firm Allecra Therapeutics. 27 February 2024
Biotechnology
Further expanding its therapeutic range, Danish diabetes and obesity giant Novo Nordisk has entered into a collaboration and licensing agreement with US biotech Neomorph to discover, develop and commercialize molecular glue degraders beyond oncology. 27 February 2024
Pharmaceutical
Swedish immunology company InDex Pharmaceuticals late yesterday announced that the development of cobitolimod is discontinued. 27 February 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the closing of its successful £40.5 million ($51.4 million) Series A financing. 27 February 2024
Pharmaceutical
California’s Tarsus Pharmaceuticals has announced positive topline results from the Phase IIa CARPO trial. 26 February 2024
Biotechnology
US biotech BioCryst Pharmaceuticals has announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat). 26 February 2024
Biotechnology
US hematology specialist Disc Medicine today announced the appointment of Pamela Stephenson as the company’s chief commercial officer. 26 February 2024
Biotechnology
On Friday, the US Food and Drug Administration (FDA) announced its final decision to withdraw the marketing authorization of Swedish biotech Oncopeptides’ Pepaxto (melphalan flufenamide). 24 February 2024
Biotechnology
Ophthalmology company Ocular Therapeutix has named what it describes as a ‘retina dream team’ alongside its announcement of a $325 million financing. 23 February 2024
Biotechnology
US pharma major AbbVie revealed yesterday that it has linked up with San Diago, USA-based start-up Tentarix Biotherapeutics on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. 23 February 2024
Biotechnology
Privately-held immuno-oncology company Immune-Onc Therapeutics has announced a Phase Ib/II trial collaboration with Swiss pharma giant Roche. 22 February 2024
Pharmaceutical
German family-owned drugmaker InfectoPharm Arzneimittel und Consilium GmbH has set up a further European subsidiary – this time in France. 22 February 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze